Merck: new positive Phase 3 results in PAH

Published: 2025-06-23 08:29:27 ET MRK

Published on 06/23/2025 at 08:29

Merck reported positive Phase 3 results on Monday in patients with pulmonary arterial hypertension (PAH) in Group 1 and Functional Class (FC) II or III according to the World Health Organization (WHO) or at high risk of progression.The trial met its primary endpoint, which was a composite endpoint including all-cause death, unplanned hospitalization for PAH lasting more than 24 hours, atrial septostomy, lung transplantation, or worsening pulmonary condition.When administered as an add-on to background therapy, Winrevair demonstrated a statistically significant and clinically relevant reduction in the risk of worsening events compared to placebo, provided it was initiated within 12 months of diagnosis.Merck emphasizes that the Phase 3 trial, which was stopped early in January due to these positive results, is the third to demonstrate the efficacy of Winrevir in adult PAH.Copyright (c) 2025 CercleFinance.com. All rights reserved.